Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x100px
Document › Details

Numares AG. (9/10/19). "Press Release: Numares Elects Kathy L. Bates as New Member of the Supervisory Board". Regensburg.

Organisations Organisation Numares AG
  Group Numares (Group)
  Organisation 2 Mayo Clinic
Products Product NMR spectroscopy
  Product 2 clinical diagnostics
Persons Person Bates, Kathy L. (Mayo Clinic 201912 Senior Director Lab Services + Partnership Developm + Numares Supersvisory Board)
  Person 2 Pfahlert, Volker (LipoFIT GmbH 201001– Managing Director COO before Roche Diagnostics + Dräger Medical)
     


numares appoints Kathy L. Bates, MBA, as new member of the Supervisory Board with immediate effect.


numares appoints Kathy L. Bates, MBA, as new member of the Supervisory Board with immediate effect. Ms. Bates is Senior Director, Laboratory Services and Partnership Development at Mayo Clinic, in Rochester, Minnesota.

“We are delighted to welcome Kathy to the board,” says Dr. Volker Pfahlert, Chief Executive Officer of numares. “As we continue our focus on North American expansion, the depth of knowledge and relevant experience in the US healthcare will be invaluable to numares.” Ms. Bates is the first member of the Supervisory Board from the US. After starting her career in 1994, Ms. Bates completed various leading positions at Mayo Clinic and its partnership organizations. Her competence profile is supplemented by a large pool of experiences serving on the board of directors of Oncospire Genetics Inc. and on a Scientific Advisory Board for Roche Diagnostics Switzerland.

Since 2005 Kathy Bates is Senior Director, Laboratory Services and Partnership Development at Mayo Clinic, leading technology evaluations and strategic business development activities in laboratory diagnostics.

Recently, numares and Mayo Clinic Laboratories announced their collaboration to develop new diagnostic tests using the “numares model” – meaning a distinctive nuclear magnetic resonance (NMR) technology, to identify metabolite constellations for diagnostics.

At the annual general meeting Ms. Bates was elected to follow Dr. Gerd Grenner, who supported numares as member of the Supervisory Board since 2014 and left his position due to private reasons. The other Board Members, Dr. Schirmers, Dr. Ries and Dr. Kutzner were reelected. Dr. Bernhard Schirmers, Chairman of the Supervisory Board, thanked Dr. Grenner in special recognition of his many years of commitment for his achievements on behalf of the Supervisory Board.


About numares

numares AG, based in Regensburg, Germany, is a fast-growing innovative diagnostics company that applies machine learning to metabolomics data to develop advanced analytical tests for high-throughput use in clinical diagnostics and life science research. The AXINON® System employs nuclear magnetic resonance (NMR) spectroscopy to create a “numaric” spectrum to evaluate metabolic constellations. Magnetic Group Signaling (MGS®) is a proprietary technology that enables NMR for highly standardized and rapid throughput testing. Metabolic tests stand as an important pillar in precision medicine to address unmet needs in cardiovascular diseases, nephrology, oncology and neurology.


For further information please contact:

numares
Julia Hertlein
Tel.: +49 941 280 949-14
E-Mail: julia.hertlein(at)numares.com

   
Record changed: 2023-06-05

Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for Numares (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group World of Partnering Opportunities 650x300px




» top